S HALL

406 total citations
12 papers, 308 citations indexed

About

S HALL is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, S HALL has authored 12 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 4 papers in Pediatrics, Perinatology and Child Health and 3 papers in Oncology. Recurrent topics in S HALL's work include Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (3 papers) and Pharmaceutical studies and practices (3 papers). S HALL is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (3 papers) and Pharmaceutical studies and practices (3 papers). S HALL collaborates with scholars based in United States and Norway. S HALL's co-authors include D. Craig Brater, Judith A. Aberg, Stacey M. Etheridge, Andrew Zolopa, Andrew J. Taylor, Jonathan R. Deeds, Michelle A. Kendall, Carl J. Fichtenbaum, J.N. Ladd and Richard Hafner and has published in prestigious journals such as Hepatology, Sensors and Actuators B Chemical and Clinical Pharmacology & Therapeutics.

In The Last Decade

S HALL

10 papers receiving 300 citations

Peers

Countries citing papers authored by S HALL

Since Specialization

Citations

This map shows the geographic impact of S HALL's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S HALL with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S HALL more than expected).

Fields of papers citing papers by S HALL

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S HALL. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S HALL. The network helps show where S HALL may publish in the future.

Co-authorship network of co-authors of S HALL

This figure shows the co-authorship network connecting the top 25 collaborators of S HALL. A scholar is included among the top collaborators of S HALL based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S HALL. S HALL is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Quantitative detection of tetrodotoxin (TTX) by a surface plasmon resonance (SPR) sensor 2007 ·Sensors and Actuators B Chemical ·Andrew J. Taylor, J.N. Ladd, Stacey M. Etheridge, Jonathan R. Deeds, S HALL, (unknown)	48
2	The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates 2006 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), S HALL	60
3	Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers 2005 ·Clinical Pharmacology & Therapeutics ·Marshall J. Glesby, Judith A. Aberg, Michelle A. Kendall, Carl J. Fichtenbaum, Richard Hafner, S HALL, (unknown), Andrew Zolopa, J G Gerber	69
4	Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil 2005 ·Clinical Pharmacology & Therapeutics ·Yang Wang, Yan Jin, (unknown), H Ho, (unknown), Zelan Hu, (unknown), S HALL	4
5	Effect of MDR1 genotype (G2677T) on the disposition of ciprofloxacin in adults 2005 ·Clinical Pharmacology & Therapeutics ·(unknown), Jamie L. Renbarger, Raj Vuppalanchi, Michael A. Miller, Raymond E. Galinsky, S HALL	3
6	1124 Do hyperlipidemic patients with elevated baseline liver enzymes have a higher risk of hepatotoxicity from HMG CO-A reductase inhibitors (statins)? 2003 ·Hepatology ·Naga Chalasani, Suthat Liangpunsakul, Michael J. Murray, J. W. Kesterson, S HALL	0
7	The interaction of diltiazem with simvastatin 2000 ·Clinical Pharmacology & Therapeutics ·(unknown), D. Craig Brater, (unknown), S HALL	98
8	The effect of estrogen replacement therapy on CYP3A activity1 1999 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), Steven Wrighton, Judith A. Clements, (unknown), S HALL	1
9	The effect of clarithromycin on human cytochrome P450 (CYP) enzymes 1999 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Yuxin Liu, S HALL, (unknown)	0
10	The interaction between CYP3A substrates in the elderly1 1999 ·Clinical Pharmacology & Therapeutics ·(unknown), Z Lin, (unknown), (unknown), (unknown), S HALL	6
11	Safety and efficacy of QW7437, a new fluorocarbon-based echocardiographic contrast agent 1997 ·Journal of the American Society of Echocardiography ·(unknown), (unknown), S HALL, Paul Grayburn	17
12	Effect of Preoperative 4’-Epidoxorubicin (Epi-Adriamycin) Treatment on the Regeneration and Function of the Liver in Partially Hepatectomized Rats 1989 ·European Surgical Research ·S HALL, B Lien, Jan Erik Paulsen, (unknown), A. Bergan, Hans Erik Rugstad	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact